Trade Name: New pharmaceutical compound. The answer on section D2.1 should be "no". But due to persisting error in the form, this answer could not be entered. This error had been notified to the servi

2 trials

Sponsors

Exponential Biotherapies Inc, Exponential Biotherapies Inc.

Conditions

Systemic inflammatory respons (SIRS) and associated acute kidney injury (AKI)

Phase 1

The effect of EA-230 on the immuneresponse

Active, not recruitingEUCTR2014-002481-78-NL

Exponential Biotherapies IncSystemic inflammatory respons (SIRS) and associated acute kidney injury (AKI)

Start: 2014-10-07Target: 60Updated: 2020-11-30

Phase 2

Study on the effects of EA-230 on the immune system following heart surgery

Active, not recruitingEUCTR2015-005600-28-NL

Exponential Biotherapies Inc.Systemic inflammatory respons (SIRS) and associated acute kidney injury (AKI)

Start: 2016-06-17Target: 160Updated: 2020-11-30